RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced the publication of a research paper co-authored by Metabolon and Teva Pharmaceutical Industries Ltd. which demonstrates the use of global biochemical profiling to better understand drug-induced nephrotoxicity.
